Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre

Yusof, Yuzaiful Md; Kabia, Angela; Darby, Michael; Lettieri, Giovanni; Beirne, Paul; Vital, Edward M; Dass, Shouvik; Emery, Paul

doi:10.1093/rheumatology/kex072

Cited by 172 publications

(131 citation statements)

References 28 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…A total of 68% of these patients improved or had stable pulmonary function after rituximab [93]. Rituximab was safe and only three patients (0.4%) developed ILD after RTX treatment, which may point towards a protective effect of rituximab [93]. A similar response was seen in smaller case series [94].…”

Section: Treatmentmentioning

confidence: 53%

“…Rituximab, a B-cell-depleting anti-CD20 antibody, was used in 700 patients with RA; 56 had RA-ILD prior to rituximab treatment. A total of 68% of these patients improved or had stable pulmonary function after rituximab [93]. Rituximab was safe and only three patients (0.4%) developed ILD after RTX treatment, which may point towards a protective effect of rituximab [93].…”

Section: Treatmentmentioning

confidence: 95%

See 1 more Smart Citation

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

Bendstrup

Møller

Kronborg-White

et al. 2019

JCM

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA) contributing to significantly increased morbidity and mortality. Other respiratory complications, such as chronic obstructive pulmonary disease and bronchiectasis, are frequent in RA. Infections and drug toxicity are important differential diagnoses and should be considered in the diagnostic work-up of patients with RA presenting with respiratory symptoms. This review provides an overview of the epidemiology and pathogenesis of RA-ILD, the radiological and histopathological characteristics of the disease as well as the current and future treatment options. Currently, there is no available evidence-based therapy for RA-ILD, and immunosuppressants are the mainstay of therapy. Ongoing studies are exploring the role of antifibrotic therapy in patients with progressive fibrotic ILD, which may lead to a new treatment approach for subgroups of patients with RA-ILD.

show abstract

Section: Treatmentmentioning

confidence: 53%

Section: Treatmentmentioning

confidence: 95%

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

Bendstrup

Møller

Kronborg-White

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Yusof et al . reported stabilisation of rheumatologic involvement in more than 55% of patients treated with anti CD20 with a contemporary improvement of functional respiratory data in more than 15% of patients and Matteson et al . described the clinical and functional stabilisation of ILD involvement in RA patients after rituximab therapy.…”

Section: Discussionmentioning

confidence: 99%

“…22 However, a high incidence of pulmonary toxicity is reported in patients treated for lymphoma and/or in some patients with RA. 23 Controversial results have been reported on rituximab efficacy in RA-ILD patients [24][25][26] and our study will contribute to this topic by describing the characteristics of 28 patients treated with RA-ILD focusing mainly in those with anti-CD20.…”

Section: Introductionmentioning

confidence: 98%

Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis

Fui

Bergantini

Selvi

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. In this disease, interstitial lung diseases (ILD) is associated with high risk of mortality. Rituximab, a monoclonal antibody directed against CD20, is effective in the treatment of articular manifestations in RA while controversial results have been reported on rituximab efficacy in RA‐ILD patients. Aims To describe the clinical and radiological characteristics of 28 patients with RA‐ILD and analyse the efficacy of anti‐CD20 therapy in 14 RA‐ILD patients treated with this drug for more than 1 year. Results In our population, high resolution computed tomography features revealed usual interstitial pneumonia (UIP) in 15/28 (54%) of patients, non‐specific interstitial pneumonia in 8/28 (29%) patients, other patients presented fibroelastosis and nodular fibrotic patterns. Higher mortality rate was observed in RA patients with radiological UIP pattern compared to those with different radiological patterns, although our patients with RA associated with radiological UIP pattern had a longer survival (7 years from ILD diagnosis) compared with literature data (3–5 years from ILD diagnosis). Half of our patients were treated with rituximab and they had a progressive reduction of lung function parameters. After 6 and 12 months of anti‐CD20 therapy, our patients presented a stabilisation of lung function parameters. Conclusion Our study supported the theory that patients with RA and radiological UIP pattern at computed tomography scan presented the worst survival; rituximab therapy seems to be effective stabilising ILD involvement and lung function deterioration.

show abstract

“…В заключение необходимо подчеркнуть, что, соглас-но клиническим рекомендациям Ассоциации ревматоло-гов России, при выборе РТМ в качестве «первого» ГИБП при РА следует принимать во внимание его высокую эффе-ктивность при РФ/АЦЦП-позитивном варианте РА [65,66], ревматоидном и криоглобулинемическом васкулитах [67][68][69][70], противопоказания для назначения ингибиторов ФНОα (аутоиммунные нарушения, злокачественные ново-образования, риск реактивации латентной туберкулезной инфекции, демиелинизирующие заболевания ЦНС), по-ложительное влияние на прогрессирование интерстици-ального заболевания легких -характерной коморбидной патологии, ухудшающей прогноз болезни [71,72].…”

Section: таблицаunclassified

The Efficacy and Safety of Rituximab Biosimilar (Acellbia®) in Rheumatoid Arthritis as the First Biological Agent: Results of Phase Iii (Alterra) Clinical Trial

Nasonov

Мазуров

Зонова

et al. 2017

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has been evidence that RTM can be used at lower doses than those given in the standard recommendations and instructions for the use of this drug. This serves as the basis for the BCD-020-4/ALTERRA (ALTErnative Rituximab regimen in Rheumatoid Arthritis) trial, the objective of which was to investigate the efficiency and safety of using Acellbia® (at a dose of 600 mg twice at a 2-week interval) as the first biological agent (BA) for methotrexate (MTX)-resistant active rheumatoid arthritis (RA). The investigation enrolled 159 patients aged 18 to 80 years with active RA. After 24 weeks 65.7 and 29.4% of patients achieved 20% improvement by the American College of Rheumatology (ACR) criteria in the Acellbia® + MTX and placebo (PL) + MTX groups, respectively (p<0.0001). The differences in the ACR20 response rate in the two groups were 36.3% (95% CI, 19.27–53.28%). There were significant differences between the groups in the ACR50 response rates: 28.4% and 5.9% (p=0.001) and in the ACR70 ones: 12.8% and only 2.0%, respectively (p=0.036). Analysis of all recorded adverse events (AE) frequency showed no significant differences between the patients in the study and control groups and demonstrates its equivalence with that of RTM (MabThera®); all the AE were expectable. It is noted that antibodies to RTM with binding and neutralizing activities had no impact on the efficiency and safety of therapy.

show abstract

Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre

Cited by 172 publications

References 28 publications

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis

The Efficacy and Safety of Rituximab Biosimilar (Acellbia®) in Rheumatoid Arthritis as the First Biological Agent: Results of Phase Iii (Alterra) Clinical Trial

Contact Info

Product

Resources

About